Hansa Biopharma — Juli 2024
-
After a Big Win, Is Sarepta Therapeutics Stock a Buy? https://proinvestor.com/investornyt/1181869/after-a-big-win-is-sarepta-therapeutics-stock-a-buy
-
Hansa Biopharma - Automatisk teknisk analys. Medellång sikt, 8 jul 2024:
Hansa Biopharma - teknisk analys av aktien - Dagens industri
Utförlig grafisk information om Hansa Biopharma historiska utveckling som ger en hint om aktiens framtida utveckling.
Dagens industri (www.di.se)
-
Direkte her hos Investtech:
-
Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update
-
Financial Performance
The Company delivered strong financial performance for the third consecutive quarter with total revenue of 54.2 MSEK. Of this, 47.1 MSEK is attributed to IDEFIRIX sales. This excludes the impact of an approximate 20 MSEK provision related to potential price adjustments from cumulative sales since the launch of IDEFIRIX in Europe in 2020. After accounting for this provision, total IDEFIRIX product sales were 27.2 MSEK.
-
Sales performance was primarily driven by continued expansion of IDEFIRIX in key European markets. To date, the Company has secured reimbursement in 14 European markets.
In Q2 2024, the Company completed a directed share issue, raising gross proceeds of 372 MSEK (US $34.6M) primarily from high-quality international healthcare specialist investors.
-
Pipeline Progress
Progress across the pipeline included the completed randomization in the ConfIdeS pivotal Phase 3 US trial in kidney transplantation, further enrollment in the European Post Approval Efficacy Study in kidney transplantation (70 percent) with expected completion by 2025, and continued enrollment (70 percent) in the GOOD-IDES-12 Phase 3 trial in anti-GBM disease with data readout in 2025.
-
HANSA BIOPHARMA: RÖRELSERESULTAT -187 MLN KR 2 KV (-229)
STOCKHOLM (Nyhetsbyrån Direkt) Bioteknikbolaget Hansa Biopharma, som förut hette Hansa Medical, redovisar ett rörelseresultat på -187 miljoner kronor (-229) för det andra kvartalet 2024.
Resultatet efter skatt blev -258 miljoner kronor (-251). Resultatet per aktie uppgick till -3:30 kronor (-4:79). ...
...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind